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GLAUCOMA: LATEST AVENUES AND ADVANCES 
INTRODUCTION:  
Glaucoma is a leading cause of blindness worldwide, characterised by progressive multifactorial 
neurodegeneration of retinal ganglion cells (RGCs) within the retinal nerve fibre layer (RNFL) and 
their corresponding axons within the optic nerve head (ONH).(1,2) It is projected to affect 79.6 
million people worldwide by 2020, of which 11.2 million will be bilaterally blind, emphasising its 
personal, economic and social burden.(3) Clinically, patients suffering from the most common 
subtype, primary open-angle glaucoma (POAG), will classically experience the progressive loss of 
their peripheral visual field, which can eventual lead to complete blindness.(4) Due to the disease’s 
asymptomatic nature, it is estimated that in the developed world only half of people affected by 
glaucoma are aware of their condition and that there is a subsequent ten-year delay between initial 
onset and diagnosis of glaucoma, by which time irreversible blindness can occur.(5,6) Glaucoma 
research currently aims to meet the need for optimisation of risk factors, diagnostics and 
therapeutic strategies in glaucoma. New avenues and advances in these fields of research are 
discussed in this review article. 
RISK FACTORS 
TRANS-CRIBROSAL AND CSF PRESSURE 
It is thought that in glaucoma the lamina cribrosa (LC) is displaced posteriorly and compressed which 
implies an unknown force acting on the LC.(7) Since the LC forms the border between the intraocular 
space with a higher pressure and the retrobulbar space with a lower pressure, a pressure gradient 
exists across the LC which is IOP minus CSF pressure in the retrobulbar space.(8) This trans-cribrosal 
pressure differential (TCPD) is thought to play an important role in the pathophysiology of glaucoma 
as it has been found that abnormal pressure gradients can affect both orthograde and retrograde 
optic nerve axoplasmic flow.(9,10) 
There have been several studies to investigate the link between glaucoma and CSF pressure which 
show that glaucoma patients tend to have lower CSF pressures. A retrospective study of patients 
undergoing lumbar punctures noted that patients’ CSF pressures appear to decline as they age from 
55 years onwards, which reflects the increased glaucoma risk beyond this age.(11) Jonas et al. found 
that a glaucoma group displayed a lower calculated CSF pressure and greater estimated translaminar 
pressure difference than a non-glaucomatous group.(12) These findings are supported by Berdahl et 
al who carried out a retrospective review of 31,787 medical records where it was found that 
normotensive glaucoma (NTG) and POAG were associated with lower mean CSF pressure in a group 
of 28 patients with open-angle glaucoma than in a control group of 49 non-glaucomatous 
patients.(13) It was also found that TCPD was significantly higher in POAG (12.5+- 4.1) and NTG (6.6 
+- 3.6) compared to control (1.4 +- 1.7) This association between TCPD and glaucoma was also noted 
by Ren et al. A prospective study of 52 patients found that neuroretinal rim area (correlation 
coefficient r = -0.38) and mean visual field defect (p = 0.008; r = 0.38) were significantly associated 
with increased trans-lamina cribrosa pressure difference.(14)  
Whether it is TCPD, lower mean CSF pressure or a combination of both that contributes to 
glaucomatous changes is unclear. A recent experimental study found that reduction in CSF pressure, 
in monkeys that had a shunt inserted, was associated with development of optic neuropathy with 
reduction in neuroretinal rim area and volume, and increase in cup-to-disc area ratios.(15) 
There are a number of questions regarding the link with CSF pressure and glaucoma. Both IOP and 
CSF pressure are dynamic and fluctuate over time and their measurements are influenced by several 
factors, thus the estimation of TCPD should be best calculated based on simultaneous 
measurements of both IOP and CSF pressure. None of the available studies did it, and they are based 
on two non-dependent and changing variables.(16) 
Recent literature review and meta-analysis showed only five studies that reported quantitative TCPD 
parameters, four based on lumbar puncture and one on noninvasive two-depth transcranial Doppler 
device.(17) Studies based on lumbar puncture CSF pressure measurement assumed that lumbar CSF 
pressure was equal to the retrolaminar CSF pressure, which was never proved and even questioned 
in several studies.(18) An interesting discussion of this is presented elsewhere.(19) Moreover, 
Hayreh advocated that TCPD caused by low CSF pressure is not able to cause bowing back of the 
rigid and compact band of lamina cribrosa and plays a role in development of optic neuropathy.(20) 
Another issue is the clinical applicability of these studies as clearly lumbar punctures are a highly 
invasive procedure, which cannot be used as a risk stratification tool in a clinical setting.  A potential 
development in this regard is the possibility of non-invasive CSF pressure telemetry. There are 
currently various potential non-invasive methods being developed such as telemetry based on 
otoacoustic emissions or transcranial doppler insonation of the ophthalmic artery.(21,22) These are 
promising areas for non-invasive CSF telemetry, which will have wide impacting clinical applications 
in medicine and perhaps could provide a use in the risk stratification of glaucoma patients too. 
IOP FLUCTUATION: 
The reduction in IOP is the mainstay of glaucoma treatment and well established as an acceptable 
method of reducing the rate of glaucomatous optic nerve damage. The use of IOP lowering 
treatments has been well supported by numerous studies such as the Ocular Hypertension 
Treatment Study and the Collaborative Normal Tension Glaucoma Study.(23,24) Such studies have 
supported the theory that lowering IOP reduced the rate of visual field loss in both POAG and NTG 
groups. Recently there has been growing interest into the importance of IOP fluctuation in the 
progression of glaucomatous damage, both in terms of short term and long term fluctuations. 
Studies reveal that IOP tends to fluctuate throughout the day and over longer intervals however due 
to lack of standardisation in experimental protocols a consensus has been difficult to achieve.(25–
27) Fluctuation of IOP can be short term in that it is diurnal or occurring over days and weeks; long 
term fluctuation is considered as occurring over months and years.   
Hong et al studied 688 eyes in patients with POAG or chronic primary angle closure glaucoma (PACG) 
who had undergone phacoemulsification after trabeculectomy. After 3 years of follow-up, patients 
with POAG and an IOP SD greater than 2 mm Hg had a significantly worse mean visual field (VF) 
deviation than did patients with an IOP SD of 2 mm Hg or less. Hence they concluded that reduced 
postoperative IOP fluctuation was statistically associated with a slower progression of VF 
damage.(28) Similar conclusions could be drawn from a cohort from the Advanced Glaucoma 
Intervention Study, which included 509 eyes with refractory OAG not well controlled with 
medication. It was found that for each 1 mm Hg increase in IOP fluctuation, the odds of VF 
progression increased by about 30%. In fact when regression analyses were repeated in eyes with 
and without a history of cataract extraction, IOP fluctuation was the only variable to be consistently 
associated with VF progression.(29) The Collaborative Initial Glaucoma Treatment Study also 
reinforced the finding that IOP peak and fluctuation were important predictors of disease 
progression at 3-9 years follow up.(30) High peak IOP, wide standard deviation and a large range of 
IOP were all linked to disease progression.  
With regards to diurnal variation most studies of repeated IOP measurements throughout the day 
have determined that values tend to peak early in the morning and decline over the course of the 
day.(31–34) Gonzalez et al carried out an analysis of daytime IOP curves from 149 patients with OHT 
found that 64 % of eyes that had a difference of more than 5 mm Hg between the peak and trough 
IOP in their diurnal curve eventually had VF defects within 4 years.(35)  
Whilst the link between IOP fluctuation and disease progression is gaining increasing evidence the 
mechanism underlying this is still not well understood. It is postulated that IOP fluctuation may 
affect homeostatic mechanisms that protect retinal ganglion cells which in turn may lead to optic 
nerve head and glial tissue damage.(36) Another theory is the chronic remodelling of LC as a result 
of fluctuation IOP leading to irreversible changes and a reduced tensile strength.(37) 
SMOKING 
A new controversial risk factor being investigated in glaucoma patients is cigarette smoking. There 
have been studies to suggest an association between smoking and POAG and also studies to counter 
this argument. The Blue Mountain Eye Study suggested a moderate positive association between 
smoking and increased IOP.(38) Fan et al found a significant association (Odds Ratio 10.8) between 
current smoking and POAG in thirty-two patients. These finding have been supported by other older 
case-control studies which also found associations with current smoking and POAG.(39,40) Whereas 
other studies have found an association with past smoking and POAG.(41,42) Renard et al found in 
339 cases of POAG was associated with higher frequency of heavy smoking (40 pack-years or more, 
OR = 3.93). 
In the meta-analysis including 7 reports, 4 cross-sectional and 3 case-control studies the odds ratio 
for POAG for current and former smokers was 1.37 and 1.03 respectively.(43) It was also shown that 
smoking might be associated with increased risk of early-onset POAG, (44) and that smoking has also 
a negative impact on POAG surgery.(45) Although smoking and alcohol consumption together 
influence glaucoma progression, it is more influenced by smoking than by alcohol consumption.(46) 
It was reported that smoking increases the expression of IL-6, as well as caspase-3 and PARP-1 in the 
aqueous humor and in plasma of POAG women aged 40–90 years.(47) 
Interestingly, in Chinese cohort smoking was significantly correlated with decreased central corneal 
thickness (CCT).(48) Although mechanism for decreased corneal thickness in POAG smokers remains 
unclear, it was suggested more attention should be paid to CCT measurement to estimate correct 
target IOP. On the other hand, several studies reported little or no evidence for any relation 
between smoking and POAG (49–51) and the recent study did not confirm the influence of chronic 
tobacco smoking on IOP.(52) Smokers and nonsmokers did not vary significantly in the prevalence of 
open-angle glaucoma and angle-closure glaucoma in adult Chinese population,(53) and in Los 
Angeles Latino population.(54) The prospective longitudinal study of 527 Caucasian POAG cases and 
1539 Caucasian controls has shown that the association between cigarette smoking and arterial 
hypertension in relation to POAG depends on nitric oxide synthase 3 isoform single nucleotide 
polymorphism.(55)  
 
Most studies that have been carried out did not categorize the number of cigarettes smoked. In the 
limited papers where this has been done, there appears to be a dose–response relationship. In a 
prospective cohort study by Wise et al. in 32,570 participants found that heavy smokers (≥20 pack 
years) were more than twice as likely to have POAG, in the group under 50 years of age.(56) 
The association with smoking and glaucoma is contentious and has been poorly investigated with 
very few high quality studies and not much risk stratification based on pack years. This is surprising 
considering the extent to which smoking has been investigated as a risk factor in most other medical 
fields. The evidence exploring the association of smoking in general with POAG is limited, however 
clinicians should consider the potential relationship with heavy smoking. More in-depth studies 
which take a detailed smoking history are most certainly required.(57) 
VASCULAR RISK FACTORS 
 
Vascular dysregulation was shown to be important risk factor for GON.(58) Primary vascular 
dysregulation, the term introduced by Flammer, described otherwise healthy subjects that show 
abnormal regulation in response to temperature changes and mechanical or emotional stress.(59) 
Low OPP was shown to be a risk factor for the prevalence, incidence and progression of glaucoma in 
large epidemiological studies.(60)  
The Barbados Eye Studies reported that baseline vascular risk factors, including decreased systolic 
blood pressure and decreased systolic, diastolic, and mean ocular perfusion pressure, can influence 
the risk of POAG.(61) Specifically, low ocular perfusion pressure doubled the risk of glaucoma in that 
population. The Early Manifest Glaucoma Trial reported that baseline predictors of progression of 
open-angle glaucoma include decreased ocular systolic perfusion pressure, a history of 
cardiovascular disease, and decreased systolic blood pressure.(61) The Thessaloniki Eye Study 
showed that a diastolic blood pressure of less than 90 mm Hg due to antihypertensive treatment is 
associated with increased optic-nerve cupping and a decreased rim area of the optic disk in subjects 
without glaucoma.(62) The Proyecto VER Study (63) and the Egna-Neumarkt Study (64) reported 
that patients with diastolic perfusion pressure as low as 45-50 mmHg had 3-4.5 times risk of 
developing glaucoma compared to those with diastolic perfusion pressure of 65 mmHg. 
Interestingly, vascular factors were shown to play significant roles in the pathogenesis of many 
neurodegenerative diseases, including Alzheimer’s disease and amyotrophic lateral sclerosis.(65,66) 
LIGHT TOXICITY AS A RISK FACTOR  
It was also proposed by Osborne and collaborators that visual light might be a factor for explaining 
why retinal ganglion cells might be particularly susceptible in mitochondrial diseases and 
glaucoma.(67) They showed that mitochondrial failure occurs when the disease is initiated and also 
as a secondary event, exacerbated when the cells are nutritionally deprived.(68) Moreover, they 
suggested that patients with glaucoma might benefit from reducing the intensity of light entering 
the eye.  
DIAGNOSIS AND MONITORING 
Glaucoma remains a disease whose effects are largely irreversible even when using the latest 
therapeutic interventions, therefore early disease detection remains the main approach by which 
ophthalmologists prevent visual impairment. Currently the two main strategies used in a clinical 
setting to assess the structure and function of the optic nerve are optic nerve imaging and perimetry 
respectively. In addition to these established techniques further strategies have emerged which 
offer promising prospects for early diagnosis and better monitoring in glaucoma.  
OPTICAL COHERENCE TOMOGRAPHY (OCT)  
OCT provides a significant role in aiding diagnosis in glaucoma. It delivers an accurate measurement 
of the retinal nerve fibre layer (RNFL) thickness which can then be used to make a quantifiable 
assessment of glaucomatous structural loss (69). OCT’s ability to produce high resolution images in a 
non-invasive manner makes it particularly attractive as a diagnostic tool in glaucoma. 
Traditionally Time Domain OCT (TD-OCT) has been used to aid diagnosis but this has since been 
usurped by a newer generation technology, Spectral Doman OCT (SD-OCT) (70). SD-OCT provides up 
to 200 times faster scanning speeds compared to TD-OCT, this is of particular importance in 
minimising movement artefact due to involuntary movements of the eye. Furthermore the faster 
scanning speeds in conjunction with the higher density sampling provided by SD-OCT allow better 
visualisation of pathophysiological features of the retina (71,72). Also SD-OCT has better axial 
resolution compared to TD-OCT, with SD-OCT (3-6 µm) shown to improve axial resolution by two-
three times as compared to TD-OCT (10 µm) (69). Ensuring that results are reproducible is important 
in maintaining an accurate diagnosis of glaucoma, studies that looked specifically at the 
reproducibility of both modalities found that a key measure of glaucoma, the sectorial RNFL 
thickness had significantly less variability in the SD-OCT group as compared to TD-OCT (73,74). 
Additionally different SD-OCT devices (Cirrus and RTVue OCT) have shown consistently good 
reproducibility (75,76). Encouragingly SD-OCT has shown to be better at sectorial measurement 
which is of particular importance as glaucomatous damage typically presents as a localised defect in 
its earlier stages before spreading. 
As described previously glaucomatous damage manifests as a structural and functional decay of the 
optic disc, OCT provides an assessment of structural damage with visual field assessment functional 
loss. Horn et al was able to demonstrate a correlation between structural damage viewed by OCT 
and functional loss as visual field defects, of note a strong correlation was seen in the peripapillary 
areas of the retina (77). Furthermore the study used another modality to assess structural damage, 
scanning laser polarimetry (SLP) and found that SD-OCT showed better associations between 
perimetric defect and corresponding RNFL loss than SLP (77). However another study comparing TD-
OCT and SD-OCT found there to be no significant difference in the strength of structural-functional 
relationship between the two devices (73).  
It is hoped that as the SD-OCT technique improves it will be capable of diagnosing glaucoma before 
gold standard perimetry and optic nerve head assessment. So far studies have shown SD-OCT 
provides improved reproducibility as compared to TD-OCT therefore improving SD-OCT’s ability to 
detect smaller changes earlier, ensuring earlier diagnosis. However due to the slow progression of 
the disease and the technologies recent emergence, there are no long term studies demonstrating 
SD-OCT’s ability to detect glaucoma in its early stages. Furthermore studies have shown readout 
variability between SD-OCT devices as each companies inbuilt software systems define the outer 
retinal border at different levels (78). For example Cirrus HD OCT delineates the outer retinal border 
as the level of interdigitation between outer segments and retinal pigment epithelium (RPE) whilst 
the Heidelberg Spectralis defines it as level of the RPE- Bruch’s membrane complex (79). Therefore a 
study comparing the readouts of the two SD-OCT systems found that the significant difference in 
values produced was due to software used rather than the devices themselves (78). 
DETECTION OF APOPTOTIC RETINAL CELLS (DARC) 
Currently the detection of glaucoma is limited by the late presentation of visual field loss symptoms 
which predominately occur in the later stages of disease. This delay limits the efficacy of therapeutic 
interventions. It is thought that by the time patients develop visual field loss approximately 40 
percent of RGCs have been lost through apoptosis (12) with previous post-mortem and histological 
studies corroborating these findings. The realisation that the early diagnosis of glaucoma can be 
effective in slowing down disease progression has meant that recent research has focused on 
identifying early diagnostic markers. The apoptosis of RGCs is one of the first stages that occur in 
glaucoma (13,14) thereby showing great promise as a prospective early diagnostic tool. 
DARC technology has the potential to directly visualise these apoptosing RGC’s thereby providing 
early diagnosis and the ability to accurately monitor the efficacy of treatment. Annexin V plays a 
pivotal role in DARC technology due to its ability to bind to negatively charged phospholipids in the 
presence of Ca2+ thereby enabling it to identify cells of interest undergoing apoptosis in vivo. By 
using a combination of non-radioactive fluorescently labelled annexin V and high resolution imaging, 
DARC is able to detect RGC apoptosis in real- time (15). The fluorescently labelled Annexin V is 
administered intravitreally (13), the annexin V-bound fluorophore is then excited using a 488 nm 
wavelength argon laser. The fluorescence light emission is then detected by a photodetector system 
with a 521-nm cut-off filter, finally the retina is imaged with a confocal laser scanning 
ophthalmoscope (16).  
DARC technology has been used in animal models of glaucoma such as the OHT where it has 
successfully shown a good correlation with well recognised histological endpoints (17). Furthermore 
DARC has been used to evaluate neuroprotective strategies in animal models of glaucoma which 
include amyloid-beta targeting therapy (18), glutamate modulation (19) and topical Coenzyme Q10 
(18). It is envisaged that DARC can provide a snapshot of the number of dying RGC’s at one time 
point thus giving a “DARC count” (20).  
So far the technology has been demonstrated in multiple animal models of neurodegenerative 
disease with the results of phase 1 clinical trials assessing safety and toxicology due to be published 
later this year. In conclusion DARC provides an exciting biomarker of real-time in vivo RGC death for 
glaucoma and potentially for other neurodegenerative diseases as well. 
INTRAOCULAR PRESSURE (IOP) TELEMETRY  
Growing evidence suggests that peak IOP and IOP fluctuation can vary markedly in individuals with 
glaucoma, this is of particular importance as the timing and type of treatment effects fluctuation in 
different ways (21,22). Therefore technologies that are able to detect these variations have great 
potential to provide ophthalmologists with the required information to tailor treatments to suit each 
individual’s type of glaucomatous disease and so slow the rate of progression.  
Continuous IOP measurement is required to detect IOP fluctuations; this has led to the development 
of modern technologies that can accurately measure continuous IOP through implantable sensors. 
One of the first implantable sensors was developed by Svedberg (91) who incorporated an IOP 
sensor into the implanted artificial intraocular lens (IOL) during cataract extraction. IOP 
measurements were collected by an external detector assimilated into devices such as glasses. To 
date this technology has only been reported in vitro with plans for in vivo studies (91). Further to this 
in vivo animal studies incorporating modern microchip technology into intraocular lenses implanted 
into enucleated rabbit and porcine eyes produced similar IOP readings to those collected using 
standard pneumotonometry in vitro and in vivo. A miniaturized electronic capacitive pressure sensor 
was incorporated into a single microchip with readings detected by an external device using 
magnetic high-frequency transmission. This technology was limited by the size of the device as it was 
too large to fit within the capsular bag for long-term implantation (92). Although both technologies 
have not translated into human studies, these technologies provide an advantage for glaucoma 
patients requiring cataract extraction by reducing the need for multiple procedures and so reducing 
the risk of post-operative endophthalmitis.  
A different method of continuous IOP measurement involves the insertion of an unpowered 
parylene pressure tube sensor into the anterior chamber (AC). The thin walled tube undergoes 
angular deformation in response to IOP changes which can be detected by physicians or by the 
patient themselves using stereoscopes or magnifying equipment (93,94). The main advantages of 
this technology are its biocompatibility and low running costs as no electronic transmission is 
required to detect IOP values. However nocturnal readings cannot be taken when the patient is 
asleep as the AC needs to be visualised, furthermore patients already with peripheral field loss may 
have difficulty seeing the deformations. At present the technology is undergoing in vitro testing to 
assess effectiveness and tolerability in the AC.  
One device that has been used in human clinical trials developed by Implandata GmbH uses a 
capacitive sensor to allow continuous IOP monitoring. The lens can be implanted either in the 
capsular bag or the sulcus between the capsular bag and iris and is encompassed by a biocompatible 
silicone material allowing long term implantation (95). The attached external reader can collect up to 
3,000 measurements over a period of a month allowing continuous IOP measurement. In vivo animal 
studies have shown tolerability of the IOL and good correlation between IOP measurement and IOP 
values acquired by cannulation manometry (95). 
TREATMENT:  
Despite the complex nature of glaucoma pathogenesis, current clinical practice only offers IOP-
lowering therapies. The landmark glaucoma trials, including the Ocular Hypertension Treatment 
Study (OHTS), the Early Manifest Glaucoma Trial (EMGT), the Advanced Glaucoma Intervention 
Study (AGIS) and the Collaborative Normal Tension Glaucoma Study (CNTGS), have demonstrated 
that lowering IOP in most glaucoma patients is beneficial.(96–101) Indeed, it is the most important 
modifiable risk factor for glaucoma. However it has been observed that IOP level is not proportional 
to disease progression and that disease progression can still occur in patients with drug controlled 
IOP and in patients with an IOP less than 21 mmHg.(97,99) These patients are categorised as having 
NTG, which consists of up to one half of sufferers of POAG.(102) There is therefore an urgent need 
to develop therapeutic targets independent of IOP. This has led to an interest in the role of novel 
neuroprotective agents in the treatment of glaucoma. The value of neuroprotective agents is that 
they have the potential to diminish the final common pathway of glaucoma pathogenesis, RGC 
apoptosis, which may itself be caused by a range of aetiologies. Therefore, they may be either used 
alone or in tandem with other therapeutic agents. 
Current glaucoma treatment includes pharmacological agents, of which there are five main classes 
(cholinergic, B-blockers, alpha-blockers, prostaglandin analogues and carbonic anhydrase inhibitors), 
laser therapy and surgery. However, in over half of patients with ocular hypertension or glaucoma, 
monotherapy fails to maintain target IOP.(103) New, effective IOP-lowering medications are thus 
sought, as summarised in TABLE 1. 
Table 1: New drugs in development for glaucoma 
New drug classes  Examples 
RHO inhibitors AMA0076(104), AR-13324(104), K-115(104) 
Neurotrophic agents CNTF(105), BDNF(105), NGF(105) 
Glutamate antagonists Memantine(106) 
Alpha-2 adrenergic agonists Brimonidine(107) 
Calcium channel blockers Nimodipine(108), nilvadipine(109), brovincamine(109) 
Antioxidants Coenzyme Q10(110,111) 
Anti-inflammatory Anti-TNFα(112) 
Increasing ocular blood flow Betaxolol(113) 
Other Caffeine(113), antihypertensives(113), gingko biloba extract(113) 
RHO KINASE INHIBITORS: 
The Rho family is a group of small guanosine-triphosphatase (GTP) binding proteins (RhoA, RhoB and 
RhoC), which regulate cell shape, motility, proliferation and apoptosis throughout the body through 
their effects upon actin-myosin.(114,115) The discovery of Rho kinase expression in trabecular 
meshwork, ciliary muscle cells and optic nerve head has led to their considerable interest in 
glaucoma research.(116) Furthermore, work has demonstrated higher levels of RhoA in 
glaucomatous optic nerve heads compared to age-matched controls.(98)  
In the Rho-dependent signal transduction pathway, Rho is activated upon binding to GTP, which 
further stimulates downstream effector Rho associated coiled coil-forming protein kinases (ROCK1 
and ROCK2) to polymerize actin. ROCK activation leads to phosphorylation of myosin light chain 
(MLCK) and LIM kinases. MLCK induces actin fibre contractility and LIM kinases increase cell 
migration, together obstructing aqueous humour outflow.(117–119) Thus, ROCK inhibitors can 
enhance aqueous humour drainage by inhibiting MLCK and LIM phosphorylation and thereby 
inhibiting the contractility and cellular motility within the trabecular meshwork, Schlemm’s canal 
and ciliary muscle.(120–122) Research into ROCK inhibitors that can affect cellular cytoskeleton and 
motility of the components of the conventional outflow pathway has led to a potential new ocular 
antihypertensive class.  
Y-27632 was the first ROCK specific inhibitor discovered.(123) Multiple studies since have 
demonstrated that ROCK inhibitors can lead to a reduction in IOP.(111–113) A significant challenge is 
identifying ROCK-specific inhibitors, which do not affect other protein kinases; chronic glaucoma 
usage could otherwise lead to a profound side effect profile. There have been several clinical trials 
for glaucoma investigating ROCK inhibitors. Hyperaemia is also one of the main reasons why this 
drug class has not progressed through clinical trials..(104) 
Current ROCK specific inhibitors in clinical trials include: 
1. AMA0076 caused altered cellular behaviour in human trabecular meshwork cells, reducing 
aqueous outflow resistance and thereby reducing IOP in ocular normotensive and hypertensive 
rabbits without significant adverse effects.(126) Phase 2 study was completed in January 2015; 
results are awaited. (https://clinicaltrials.gov/show/NCT02136940) 
2. AR-13324 is currently in Phase 3 Clinical Study (https://clinicaltrials.gov/show/NCT02207621). AR-
13324 is a “dual-action” ROCK inhibitor shown to both reduce aqueous humour inflow, as well as 
increase the facility of aqueous outflow. Phase 2 clinical trials showed that AR-13324 topical 
administration once daily led to an IOP reduction of 5.7mmHg.(127) It has also been combined with 
latanoprost to form a “triple-action” glaucoma drop PG324.(128) Phase 2 clinical trials completed 
in January 2016 and showed PG324 lowered IOP by 1.9 and 2.6mmHg compared to latanoprost 
and AR-13324 respectively alone after once daily usage for 28 days.(110) 
3. K-115 (ripasudil): Oral administration of K-115 ROCK inhibitor in mice led to delayed RGC death, 
demonstrating its therapeutic potential in glaucoma. Evidence suggests its mechanism is by 
modulation of the conventional aqueous outflow route, leading to aqueous outflow via the 
trabecular meshwork.(110–112) Administration of K-115 as monotherapy over 52 weeks in a large 
multicenter prospective study including 388 patients with glaucoma, OHT or exfoliation glaucoma 
revealed an IOP-lowering effect, with a mean IOP reduction of -2.6 and -3.7 at trough and peak 
respectively.(132) Furthermore, additive IOP-lowering effects were seen when used in conjunction 
with prostaglandin analogues or beta-blockers. Side effects included a mild self-resolving 
conjunctival hyperaemia in 74.6% of patients. The phase 3 study showed similar IOP-reduction 
effects after only 8 weeks of treatment when used with latanoprost or timolol.(94) Recent work 
has shown the effects of K-115 on trabecular meshwork and schlemms canal cells in vitro.(96) Work 
has shown that K-115 inhibits both ROCK1 and ROCK2 more potently than other Rho-kinase 
inhibitors.(97)  
Aside from causing a reduction in IOP, ROCK inhibitors have also been demonstrated to use other 
mechanisms in glaucoma treatment; (i) increasing ocular blood flow, (ii) retinal ganglion cell survival 
and axon regeneration, (iii) anti-fibrotic and anti-scarring agent in glaucoma filtering surgery and (iv) 
inhibit corneal endothelial cell dysfunction.(133) 
NEUROPROTECTIVE AGENTS: 
Research over the last decade has demonstrated good evidence that neuroprotective therapy is 
effective in glaucoma, which has been well outlined in recent reviews.(105,134) Neuroprotection is 
the preservation of structure and function or neuronal tissue. In glaucoma, it has the potential to 
promote cell survival and reduce degeneration of optic nerve structure and function in those 
patients showing glaucomatous changes. Whilst the pathogenesis of glaucoma is complex, several 
pathways are implicated, including ischaemia, oxidative stress, neurotropic growth factor 
deprivation, glutamate excitotoxicity, autoimmunity, calcium toxicity and mechanical compression. 
Neuroprotective agents aim to reduce glaucoma progression by targeting these pathways, thereby 
increasing retinal ganglion cell and optic nerve head function.  
The Low Pressure Glaucoma Treatment Study (LoGTS) was the first study to demonstrate that 
neuroprotective therapies have potential as glaucoma therapeutics. LoGTS was a randomized 
double-masked multi-centre clinical trial, comparing visual field progression in NTG treated with 
either the alpha α2 adrenergic agonist brimonidine or timolol.(135,136) Brimonidine has been shown 
to have neuroprotective effects in in vitro and animal studies.(137,138) Results showed that 9.1% of 
brimonidine-treated patients experienced field progression compared to 39.2% of timolol-treated 
patients, whilst mean IOP decreased equivocally in both groups. This suggests that brimonidine may 
be having a beneficial effect on visual function independently of IOP.  
However, several issues may have contributed to inaccuracy of this finding. Firstly, there was a 
higher drop-out rate of patients from the brimonidine-treated cohort due to drop-allergy. This group 
may have removed a field progressing subset of patients. Secondly, there may have been diurnal IOP 
variation between the two cohorts of patients. Thirdly, the apparent neuroprotective effect of 
brimonidine could in fact have reflected faster field progression in the timolol-treated group.(136) 
Memantine is the best-known NMDA antagonist and is approved for usage in Alzheimer’s Disease. 
Animal glaucoma models suggested that memantine is protective against retinal ganglion cells.(106) 
Despite promising pre-clinical findings, results from a clinical study of memantine usage in glaucoma 
in 2010 were unfortunately never published.  
Calcium channel blockers (CCBs) also have a good evidence base for therapeutic usage in 
glaucoma.(139) Oral nimodipine in normotensive glaucoma patients led to improved colour 
sensitivity and visual feeds compared to placebo, by vasodilation and subsequent increased ocular 
blood flow to the optic disc. (108,140) Other CCBs including nilvadipine and brovincamine have also 
shown to have visual benefit in glaucoma patients and in vitro work has demonstrated 
neuroprotective effects of CCBs on RGCs undergoing apoptosis and necrosis.(109) 
Other promising treatment strategies which are further from clinical usage but have shown to be 
neuroprotective in animal models of glaucoma, include neurotrophic factors, such as brain-derived 
neurotrophic factor (BDNF) and ciliary neurotrophic factor (CNTF).(141) A CNTF-secreting device (NT-
501) has entered clinical trials, where it is surgically implanted into the pars plana of glaucoma 
patients, allowing the drug to diffuse out.(105) Initial results have shown this is a safe device and 
possible efficacy. Some of the 11 patients displayed no progression in the implanted eye, when the 
fellow eye deteriorated. Nerve growth factor (NGF) is another promising neurotrophic factor studied 
in glaucoma treatment. In a small scale recently reported trial, NGF eye drops were administered 
topically and after three months of treatment, there was significantly less RGC apoptosis, improved 
optic nerve function, improved visual fields and visual acuity compared to untreated controls.(142) 
Oxidative stress suppression is also a promising avenue of glaucoma treatment. Coenzyme Q10 is a 
potent anti-oxidant that has been shown to be beneficial in neurodegenerative diseases, Parkinson’s 
Disease and Huntington’s Disease.(111) Recent evidence has also shown retinal benefits when used 
with Vitamin E in glaucoma patients.(110) 
Activation of the immune system may play an important role in glaucoma progression. A key pro-
inflammatory cytokine TNF-α is secreted by defective glial cells and leads to subsequent RGC 
apoptosis.  The anti-TNF-α blocker etanercept has been effectively used in patients for clinical 
indications including juvenile arthritis, rheumatoid arthritis and ankylosing spondylitis.(112) A recent 
study using intraperitoneally injected etanercept in a glaucoma rat model led to reduced axonal 
degeneration and RGC loss.(112) Further animal work and clinical studies will need to elucidate its 
full therapeutic potential in glaucoma.  
Recent work has also demonstrated the potential of caffeine to both reduce IOP when administered 
orally in ocular hypertensive rodent models, as well as diminish RGC loss.(143) This suggests a 
potential therapeutic role of caffeine and adenosine receptor antagonists in glaucoma. Oral 
administration of losartan also led to reduced RGC loss in mouse models of glaucoma.(144) 
SURGERY: 
Table 2: New surgical developments 
Surgical Procedure Example 
Increasing trabecular outflow by bypassing TM Trabectome(145), iStent(146), Hydrus(147), 
GATT(148) 
Increasing uveoscleral outflow via 
suprachoroidal pathways 
CyPass(149), iStent supra(150), SOLX Gold 
microshunt(151) 
Reducing aqueous production from ciliary body EyeOP1(152) 
Creating a subconjunctival drainage pathway Xen45(150), ExPress(153) 
 
Newer surgical devices are IOP–lowering therapies that aim to be less invasive than trabeculectomy 
surgery (TABLE 2). Techniques that are quick and easy to use, have minimal tissue instrumentation 
and feature a low complication rate and short recovery profile are more likely to be successfully 
established within the clinical setting.  
The subconjunctival space is the traditional outflow pathway used in glaucoma surgery. Xen45 
(Allergan) is the most promising glaucoma micro-implant.(154) It is a 45nm-wide, 6mm-long 
collagen-derived gelatin and glutaraldehyde tube, which is injected via an ab interno approach, to 
form a pathway from the anterior chamber to the subconjunctival space. Upon hydration, it 
becomes flexible so can conform to surrounding tissues, reducing the risk of erosion. While there is 
minimal published data on the Xen45 in partulcular, the Xen63 and Xen140 demonstrated an IOP 
reduction from 22.4 ±4.2mmHg to 15.4 ±3.0mmHg 12 months post-operatively.(154) Furthermore, 
the number of medication classes reduced from 2.5 ±1.4 to 0.9 ±1.0. No adverse events have been 
reported so far. Xen45 is currently undergoing phase 4 clinical trials.  
The EX-PRESS glaucoma filtration device is a stainless steel drainage tube, which shunts aqueous 
humour from the anterior chamber to the subconjunctival space. It is designed to enable stable 
filtration, reducing the risks of hypotony post-trabeculectomy. Additionally, it replaces the need for 
sclerectomy or iridectomy. Two meta-analyses have shown that the EX-PRESS device lowers IOP 
comparatively to trabeculectomy surgery and is associated with similar operative success and visual 
outcomes.(155,156) Recent work has also demonstrated that the EX-PRESS device is associated with 
fewer post-operative complications of hyphaema and post-operative inflammation than 
trabeculectomy surgery.(153) 
The Ologen implant is a biodegradable collagen matrix implant which is inserted beneath the 
conjunctiva following trabeculectomy. It aims to reduce fibrosis and helps in organisation of the 
subconjunctival scar formation. Recently published five-year follow up data has demonstrated that 
Ologen implant is as efficacious as MMC in terms of bleb-complication rate.(157) 
The Trabectome is an electrical device that ablates the trabecular meshwork via gonioscopy surgery, 
thus lowering resistance to aqueous outflow. IOP outcomes have been equivalent to trabeculectomy 
surgery, with the main complication being intraoperative hyphaema in up to 100% of cases.(109) A 
recent review and meta-analysis of Trabectome outcomes illustrated that it reduces IOP by 31% and 
has an overall average success rate of 66% after two years.(158) 
The Glaukos iStent is a titanium implant which may be inserted into Schlemm’s canal through the 
trabecular meshwork. It allows IOP reduction and reduced additional pharmacological medications 
when combined with phacoemulsification surgery. A prospective trial of 99 patients followed up 
over 12 months demonstrated an a reduction in preoperative medication burden in 86.9% of open 
angle glaucoma patients when two iStent injects were implanted, with no significant side effects or 
complications.(146) These second generation iStents have been found to be more effective at IOP 
reduction than the original iStent, due to the ease of inserting multiple stents at one time.  
Another promising Schlemm’s canal stent is the Hydrus, which is currently in clinical trials. This 8-mm 
long stent is made from nitinol, a mixture of nickel and titanium, which confers optimal elasticity and 
biocompatibility to open up the drainage canal, lowering IOP. A prospective randomised controlled 
trial consisting of 100 patients randomised to treatments of either Hydrus stent with cataract 
surgery or cataract surgery alone in reducing IOP. The proportion of patients after 24 months using 
no antihypertensive medications was significantly higher in those co-treated with Hydrus stent and 
cataract surgery (73 vs 38%; p=0.0008).(147) Further studies are currently ongoing, comparing the 
Hydrus stent to the iStent.(Clinicaltrials.gov) (NCT02024464) 
Suprachoroidal stents are designed to provide a direct drainage route from the anterior chamber to 
the suprachoroidal space. The CyPass micro-shunt is a 6mm shunt also designed for usage during 
cataract surgery.(149) It is inserted into the suprachoroidal space and allows aqueous flow via the 
uveoscleral pathway. As it is inserted via the ab interno route, it preserves the conjunctiva. Whilst 
unassociated with major side effects or complications, the most frequent adverse effect included 
transient hypotony. The iStent supra is another stent very similar to the CyPass, which drains directly 
into the suprachoroidal space. Although results are unpublished, early results appear to be 
promising.(159) 
The SOLX Gold shunt is an ab externo device composed of two rectangular-shaped gold plates with 
channels within its body. It is placed within the anterior chamber, with its posterior end in the 
suprachoroidal space, so as to allow aqueous flow across it.  It may be adjusted post-operatively to 
affect flow, by targeting laser onto windows within its remaining channels. Success rates in clinical 
trials have demonstrated this device to be equivocal with usage of the Ahmed valve.(151) However, 
further work will need to demonstrate safety and efficacy.  
EyeOP1 is a miniature delivery device, which reduces aqueous fluid production by destroying part of 
the ciliary body by ultrasound. In a 12-month multi-centre prospective trial, IOP reduction of 34% 
was achieved and sustained by the end of the study upon EyeOP1 usage.(152) No serious adverse 
effects were identified. 
In surgical glaucoma, gonioscopy ab-interno trabeculotomy (GATT), as described by Grover et al is an 
ab interno approach to a circumferential 360 degree trabeculectomy and optimises the safety profile 
by eliminating scleral and corneal dissection.(136) After 12 months following surgery, IOP had 
decreased by 11.1mmHg (SD, 6.1mmHg; 39.8% [SD 16.0%]) with 1.1 fewer glaucoma medications. 
Though long-term data is still needed, it is a promising technique, which is highly cost-effective. 
NEW DRUG DELIVERY METHODS UNDER DEVELOPMENT 
Despite the plethora of research into new and exciting glaucoma treatments, patient adherence 
remains a key obstacle in their benefit. Several novel delivery systems have been designed to 
optimise patient adherence and maximise IOP lowering potential.(160,161) These are summarised in 
TABLE 3. 
Table 3: Drug Delivery Methods 
Drug delivery method Description 
Traditional Orally Eg: acetazolamide. Normally for when IOP very high despite maximal 
topical therapy. Negatives: systemic side effects, low ocular 
bioavailability due to blood-retina barrier 
 Topical Eye Drops 
and Gels 
Uses: Current standard for glaucoma treatment. Gels reduce dose 
frequency.  
Negatives: <1% of drug reaches aqueous, therefore multiple daily 
dosing required 
 Ocular inserts Eg: Ocusert(162) 
Uses: Placed in inferior fornix and delivers drug over several days 
Negatives: may fall out, discomfort, patient education needed suited 
mainly for younger glaucoma patients who have manual dexterity 
 Surgical implants Eg: CNTF(163) 
Uses: can facilitate increased delivery of drug to target tissue for 
prolonged period of time 
Negatives: cost, invasiveness of initial and subsequent surgery 
Novel Liposomes & 
nanospheres 
Eg: pilocarpine liposome encapsulation(164) 
Uses: reduce drug degradation, thereby reducing drug dosage 
Negatives: requires patient adherence and proper topical 
administration 
 Contact lenses Eg: timolol-loaded contact lenses(165,166) 
Uses: drug-eluting contact lenses can release medications over longer 
periods of time 
Negatives: requires long-term contact lens wear, drug may leak out of 
lens during storage 
 Adapted surgical 
implants 
Eg: microelectromechanical system (MEMS)(167) 
Uses: MEMS uses electrolysis to push re-loaded drug out of 
subconjunctival reservoir of device; ability to change drug size, delivery 
rate and re-load drug as frequently as needed in a clinic setting during 
routine patient visits 
Negatives: requires initial surgical implantation of device,  
 Injectable 
systems 
Eg: CNTF implant(161) 
Uses: long term release (eg 3-4 months) of drug injected in a clinic 
setting, both degradable and non-degradable polymers have been 
studied for ocular delivery 
Negatives: immune response to foreign body, poor targeting to 
retina/optic nerve 
 Punctal plugs Eg: latanoprost punctual plug delivery system (L-PPDS)  
Uses: inserted into tear duct to release desired drugs 
Negatives: patient discomfort, conjunctivitis 
 
CONCLUSION 
There are a several promising new directions of research into glaucoma risk factors, diagnostics and 
therapeutics, which aim to reduce the burden of this insidious disease. The results of these many 
ongoing clinical studies will hopefully bring a migration of these new ideas from bench to bedside.  
 
Table 4: Abbreviations 
AC anterior chamber 
AGIS Advanced Glaucoma Intervention Study  
CCB Calcium channel blockers  
CCT central corneal thickness 
CNTF ciliary neurotrophic factor  
CNTGS Collaborative Normal Tension Glaucoma Study 
CSF cerebrospinal fluid 
DARC Detection of Apoptotic Retinal Cells 
EMGT Early Manifest Glaucoma Tria 
GATT gonioscopy ab-interno trabeculotomy  
GON glaucomatous optic neuropathy 
GTP guanosine-triphosphatase  
IOL intraocular lens  
IOP intraocular pressure 
LC lamina cribrosa  
LoGTS Low Pressure Glaucoma Treatment Study  
MLCK myosin light chain kinases 
NGF Nerve growth factor  
NTG normotensive glaucoma  
OAG open angle glaucoma 
OCT ocular coherence tomography 
OHT ocular hypertension 
OHTS Ocular Hypertension Treatment Study 
ONH optic nerve head  
OPP ocular perfusion pressure 
PACG primary angle closure glaucoma  
POAG primary open-angle glaucoma  
RFNL retinal nerve fibre layer  
RGC retinal ganglion cell 
ROCK Rho associated coiled coil-forming protein 
kinases  
RPE retinal pigment epithelium  
SD-OCT Spectral Doman OCT  
SLP scanning laser polarimetry  
TCPD trans-cribrosal pressure differential  
TD-OCT Time Domain OCT  
VF visual field 
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